Fidelity International
CTMX icon

Fidelity International’s CytomX Therapeutics CTMX Stock Holding History

Fidelity International’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-112,956
Closed -$1.21M – 904
2019
Q1 		$1.21M Sell
112,956
-454,036
-80% -$6.71M ﹤0.01% 593
2018
Q4 		$8.56M Buy
566,992
+5,282
+0.9% +$78.4K 0.02% 452
2018
Q3 		$10.4M Buy
561,710
+1,695
+0.3% +$38.6K 0.02% 482
2018
Q2 		$12.8M Buy
560,015
+130,090
+30% +$3.32M 0.02% 464
2018
Q1 		$12.2M Buy
429,925
+114,962
+37% +$3.28M 0.03% 332
2017
Q4 		$6.65M Buy
314,963
+200,058
+174% +$4.15M 0.02% 387
2017
Q3 		$2.09M Buy
+114,905
New +$1.79M 0.01% 447

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International's CTMX Position: Q2 2019 in Review

Fidelity International sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 112,956 shares — an estimated $1.21M sold.

Fidelity International first reported a position in CTMX in Q3 2017 and held it in 7 quarters. The position peaked at $12.8M in Q2 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Fidelity International reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Fidelity International sold 112,956 CytomX Therapeutics shares in Q2 2019, an estimated $1.21M.
  • Fidelity International first reported a position in CytomX Therapeutics in Q3 2017 and held it in 7 quarters.
  • Fidelity International's CytomX Therapeutics position peaked at $12.8M in Q2 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Fidelity International's 13F filing for Q2 2019, filed 13 Aug 2019.